Revised Outcome.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Fredun Pharmaceuticals reported strong FY2025-26 results with standalone revenue of Rs. 6,333.27 crore, up 40% from Rs. 4,517.06 crore in FY2024-25. Profit after tax grew 60% to Rs. 332.07 crore from Rs. 208.08 crore. The company received an unmodified (clean) audit opinion. Key board decisions include recommending a 7% final dividend (70 paise per share), approving a 2:1 bonus share issue, and increasing authorised share capital from Rs. 10 crore to Rs. 50 crore. Note 5 of financial results mentions one-time tax adjustments (deferred tax of Rs. 22.06 crore and short provision of Rs. 2.77 crore) related to prior years due to first-time MSME provision impact. The auditor's report flags a delay in IEPF transfers for unclaimed dividends from FY2015-16 to FY2017-18. Consolidated PAT stood at Rs. 326.21 crore vs Rs. 197.89 crore (65% growth).
The strong revenue and profit growth with clean audit opinion is positive for shareholders. The 2:1 bonus issue will triple the number of shares outstanding, diluting EPS but signaling management confidence. The IEPF compliance delay is a minor regulatory concern. Overall financial performance shows robust growth in the pharmaceutical business.